The HDL PDS-2 system showed in a relatively short time its ability to affect the progression of HoFH, with a reduction in the burden of plaque overall highlighting its exciting potential, said Brian Ghoshhajra, MD, MBA, diagnostic radiologist and service chief of cardiovascular imaging in the Department of Radiology at Massachusetts General Hospital.
The HDL PDS-2 system showed in a relatively short time its ability to affect the progression of HoFH, with a reduction in the burden of plaque overall highlighting its exciting potential, said Brian Ghoshhajra, MD, MBA, diagnostic radiologist and service chief of cardiovascular imaging in the Department of Radiology at Massachusetts General Hospital.
Transcript
Can you discuss the initial intrigue in utilizing an acute care therapeutic device, PDS-2, as a treatment for HoFH?
The type of disease (HoFH) that we see in the first 2 decades of life is actually the kind of disease that otosclerotic patients more classically get in the last 2 decades of life. So, the ability to affect that progression—in the observation we made was that the plaque change is very intriguing. The HDL PDS-2 system is administered over a short time. So, in just 7 weeks, 7 treatments, we've observed pretty significant changes. The trial is exciting for me as well because it's one of the first times that CT angiography (CTA) could be used–we're seeing that a lot of the meeting (AHA 2019). CTA is being implemented and that's where my team came in, where we analyze the CT angiography. So, we're able to assay the entire burden of plaque in all of the arteries and find the most concerning ones, which aren't necessarily the most stenotic ones, but the ones with the biggest plaque burden. We’re able to measure that and then in a short time measure it again after the therapy, and we saw a pretty remarkable reduction in the burden of plaque overall.
It's worth stepping back and looking at what CTA can show you—we can measure the entirety of the plaque burden, but we can also look at the subtypes of plaque. If you could choose, you would have no plaque in the coronary arteries, but in this case, we have the amount of plaque burden overall, and then the amount of calcified portion that's fairly thought to be more stable. A good marker that you have is otosclerosis, but the more concerning part is the lower density plaque. Then there's a subtype where the necrotic core, which is the highest risk conferring. So, when you have plaques, you have risk of future rupture and those are the ones that are most associated with risk, and this is the one that changed most dramatically in the short time that we did the therapy.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More